1071 related articles for article (PubMed ID: 14698315)
21. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical evaluation of cyclin D1 in breast cancer.
Bilalović N; Vranić S; Basić H; Tatarević A; Selak I
Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
[TBL] [Abstract][Full Text] [Related]
23. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
25. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of Bak expression in oral tongue squamous cell carcinomas.
Xie X; Clausen OP; Boysen M
Oncol Rep; 2003; 10(2):369-74. PubMed ID: 12579274
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.
Swellam M; Ismail M; Eissa S; Hamdy M; Mokhtar N
IUBMB Life; 2004 Aug; 56(8):483-90. PubMed ID: 15545228
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
32. Oncogenes in male breast cancer.
Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2 protein expression and long-term survival in breast cancer.
Joensuu H; Pylkkänen L; Toikkanen S
Am J Pathol; 1994 Nov; 145(5):1191-8. PubMed ID: 7977649
[TBL] [Abstract][Full Text] [Related]
34. bcl-2 and apoptosis in lymph node positive breast carcinoma.
Berardo MD; Elledge RM; de Moor C; Clark GM; Osborne CK; Allred DC
Cancer; 1998 Apr; 82(7):1296-302. PubMed ID: 9529021
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
36. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
[TBL] [Abstract][Full Text] [Related]
38. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers.
Zhang GJ; Kimijima I; Abe R; Watanabe T; Kanno M; Hara K; Tsuchiya A
Anticancer Res; 1998; 18(3B):1989-98. PubMed ID: 9677455
[TBL] [Abstract][Full Text] [Related]
39. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
40. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
